Tivic Health Systems, Inc. (TIVC)
After hours:
| Previous Close | 0.2510 |
| Open | 0.2490 |
| Bid | 0.1681 x 200 |
| Ask | 0.2990 x 200 |
| Day's Range | 0.2281 - 0.2500 |
| 52 Week Range | 0.2200 - 3.2100 |
| Volume | |
| Avg. Volume | 5,027,618 |
| Market Cap | 1.472M |
| Beta (5Y Monthly) | 2.48 |
| PE Ratio (TTM) | 0.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment
SAN FRANCISCO, September 18, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes’ Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation ("ncVNS") approach.
- Business Wire
Tivic Health Accelerates VNS Commercial Strategy Development
SAN FRANCISCO, September 17, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS").
- Business Wire
Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
SAN FRANCISCO, September 13, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company’s interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactio
